Companies Combine to Form Ion Channel Consortium
News Feb 27, 2012
Together, the three companies will offer value added identification and validation of ion channel modulators. The Ion Channel Consortium combines Alion’s proprietary method for short-listing drug candidates, Specs’ reliable sourcing and synthesis of compounds, and Aurora’s patch clamp services.
Researchers now have an option that enables time and cost savings while providing a unique method to identify new drug candidates for channelopathies.
Animal venoms are the subject of study at research center based at the Butantan Institute in São Paulo. But in this case, the idea is not to find antidotes, but rather to use the properties of the venoms themselves to identify molecular targets of diseases and, armed with that knowledge, develop new compounds that can be used as medicines.